Boehringer, Sosei Heptares partner on schizophrenia treatments
11 Mar 2024
License out/inPhase 2Phase 1
Boehringer Ingelheim and UK-based Sosei Heptares have entered a global collaboration and option-to-license agreement to develop and commercialize Sosei’s portfolio of GPR52 agonistsGPR52 agonists for schizophrenia.
Under the terms of the deal, Boehringer has the exclusive option to license Sosei's GPR52 agonistsGPR52 agonists, a novel G protein-coupled receptor target, following the completion of Sosei’s ongoing phase 1 and subsequent phase 1b trial and phase 2 enabling activities with HTL0048149, a first-in-class GPR52 agonistGPR52 agonist. Sosei Heptares will sponsor the trials until the option exercise, estimated in 2025.
According to Boehringer, the development of a new schizophrenia treatment targeting GPR52 has the potential to address all three aspects of schizophrenia — ‘positive’ symptoms (psychosis, delusions and hallucinations), ‘negative’ symptoms (social withdrawal and apathy) and cognitive symptoms (attention, planning and memory deficits).
In the deal, Sosei will receive an upfront payment of $27.3 million (€25 million) from Boehringer, and is eligible for an option exercise payment of $65.6 million (€60 million) and further development, regulatory and commercialization milestone payments totaling up to $732.7 million (€670 million).
Boehringer Ingelheim has inked several deals since the start of 2024. In January, the German drugmaker signed at $2 billion+ deal with Suzhou Ribo Life Science subsidiary Ribocure Pharmaceuticals to develop treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH). This was quickly followed by a second research partnership with 3T Biosciences — this time for $538.5 million — to develop first-in-class immuno-oncology treatments.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.